Shanxi Zhendong Pharmaceutical Co.,Ltd (SHE:300158)
China
· Delayed Price · Currency is CNY 4.750
+0.110 (2.37%)
Jun 13, 2025, 3:04 PM CST
SHE:300158 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 2,920 | 2,948 | 3,607 | 3,665 | 5,028 | 4,778 | Upgrade
|
| Other Revenue | 23.6 | 23.6 | 19.37 | 63.98 | 66.1 | 69.71 | Upgrade
|
| Revenue | 2,944 | 2,971 | 3,626 | 3,729 | 5,094 | 4,848 | Upgrade
|
| Revenue Growth (YoY) | -14.85% | -18.06% | -2.75% | -26.80% | 5.07% | 10.21% | Upgrade
|
| Cost of Revenue | 1,762 | 1,812 | 1,830 | 1,894 | 2,058 | 1,825 | Upgrade
|
| Gross Profit | 1,182 | 1,159 | 1,796 | 1,834 | 3,036 | 3,023 | Upgrade
|
| Selling, General & Admin | 1,445 | 1,441 | 1,762 | 1,808 | 2,662 | 2,547 | Upgrade
|
| Research & Development | 359.78 | 349.79 | 189.43 | 178.11 | 218.73 | 136.19 | Upgrade
|
| Other Operating Expenses | 15.43 | 7.79 | -34.98 | -22.64 | 15.01 | 57.62 | Upgrade
|
| Operating Expenses | 1,815 | 1,793 | 1,896 | 1,949 | 2,887 | 2,770 | Upgrade
|
| Operating Income | -633.42 | -634.14 | -99.52 | -114.52 | 148.84 | 253.13 | Upgrade
|
| Interest Expense | -4.16 | -3.9 | -1.21 | -13.78 | -19.63 | -20.85 | Upgrade
|
| Interest & Investment Income | 33.63 | 47.64 | 54.67 | 60.7 | 2,959 | 17.02 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.13 | -0.13 | 0 | 0 | - | 0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.21 | -2.55 | -11.07 | 28.7 | -20.72 | -1.93 | Upgrade
|
| EBT Excluding Unusual Items | -605.29 | -593.08 | -57.12 | -38.9 | 3,068 | 247.38 | Upgrade
|
| Impairment of Goodwill | -24.74 | -24.74 | - | - | -0.49 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -141.24 | -139.44 | 1.96 | 11.59 | 0.83 | 0.01 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.23 | 10.54 | 0 | -0.86 | -0.49 | -10.73 | Upgrade
|
| Asset Writedown | -13.04 | -18.77 | -7.62 | -0.94 | -13.15 | -0.02 | Upgrade
|
| Other Unusual Items | -555.3 | -549.54 | 25.09 | 23.84 | 61.62 | 86.22 | Upgrade
|
| Pretax Income | -1,339 | -1,315 | -37.69 | -5.28 | 3,116 | 322.86 | Upgrade
|
| Income Tax Expense | 14.88 | 17.92 | 10.18 | 51.72 | 506.49 | 69.29 | Upgrade
|
| Earnings From Continuing Operations | -1,354 | -1,333 | -47.87 | -57 | 2,610 | 253.57 | Upgrade
|
| Minority Interest in Earnings | 3.77 | 4.38 | 3.89 | 5.71 | 7.8 | 8.45 | Upgrade
|
| Net Income | -1,351 | -1,329 | -43.98 | -51.29 | 2,617 | 262.03 | Upgrade
|
| Net Income to Common | -1,351 | -1,329 | -43.98 | -51.29 | 2,617 | 262.03 | Upgrade
|
| Net Income Growth | - | - | - | - | 898.92% | 83.54% | Upgrade
|
| Shares Outstanding (Basic) | 1,008 | 1,024 | 1,028 | 1,028 | 1,027 | 1,028 | Upgrade
|
| Shares Outstanding (Diluted) | 1,008 | 1,024 | 1,028 | 1,028 | 1,027 | 1,028 | Upgrade
|
| Shares Change (YoY) | -2.84% | -0.38% | -0.02% | 0.04% | -0.01% | 0.01% | Upgrade
|
| EPS (Basic) | -1.34 | -1.30 | -0.04 | -0.05 | 2.55 | 0.26 | Upgrade
|
| EPS (Diluted) | -1.34 | -1.30 | -0.04 | -0.05 | 2.55 | 0.26 | Upgrade
|
| EPS Growth | - | - | - | - | 898.98% | 83.59% | Upgrade
|
| Free Cash Flow | -709.16 | -448.3 | -365.39 | -64.49 | 132.79 | 37.98 | Upgrade
|
| Free Cash Flow Per Share | -0.70 | -0.44 | -0.36 | -0.06 | 0.13 | 0.04 | Upgrade
|
| Dividend Per Share | - | - | - | - | 2.800 | 0.070 | Upgrade
|
| Dividend Growth | - | - | - | - | 3900.00% | 40.00% | Upgrade
|
| Gross Margin | 40.15% | 39.00% | 49.54% | 49.20% | 59.60% | 62.36% | Upgrade
|
| Operating Margin | -21.52% | -21.34% | -2.74% | -3.07% | 2.92% | 5.22% | Upgrade
|
| Profit Margin | -45.88% | -44.72% | -1.21% | -1.38% | 51.39% | 5.41% | Upgrade
|
| Free Cash Flow Margin | -24.09% | -15.09% | -10.08% | -1.73% | 2.61% | 0.78% | Upgrade
|
| EBITDA | -528.98 | -526.26 | 22.15 | 11.49 | 273.97 | 419.42 | Upgrade
|
| EBITDA Margin | -17.97% | -17.71% | 0.61% | 0.31% | 5.38% | 8.65% | Upgrade
|
| D&A For EBITDA | 104.43 | 107.88 | 121.68 | 126.01 | 125.13 | 166.29 | Upgrade
|
| EBIT | -633.42 | -634.14 | -99.52 | -114.52 | 148.84 | 253.13 | Upgrade
|
| EBIT Margin | -21.52% | -21.34% | -2.74% | -3.07% | 2.92% | 5.22% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 16.25% | 21.46% | Upgrade
|
| Revenue as Reported | 2,944 | 2,971 | 3,626 | 3,729 | 5,094 | 4,848 | Upgrade
|
| Advertising Expenses | - | 1.09 | - | - | - | - | Upgrade
|
Updated Oct 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.